ChemicalBook >> CAS DataBase List >>VU0661013

VU0661013

CAS No.
2131184-57-9
Chemical Name:
VU0661013
Synonyms
VU661013;VU0661013;1H-Indole-5-carboxylic acid, 3-[(4R)-7-chloro-10-[3-(4-chloro-3,5-dimethylphenoxy)propyl]-3,4-dihydro-4-methyl-1-oxo-6-(1,3,5-trimethyl-1H-pyrazol-4-yl)pyrazino[1,2-a]indol-2(1H)-yl]-1-methyl-
CBNumber:
CB04845069
Molecular Formula:
C39H39Cl2N5O4
Molecular Weight:
712.66
MDL Number:
MOL File:
2131184-57-9.mol
Last updated:2023-09-04 15:51:00

VU0661013 Properties

Boiling point 906.4±65.0 °C(Predicted)
Density 1.37±0.1 g/cm3(Predicted)
storage temp. Store at -20°C
solubility ≥125mg/mL in DMSO;insoluble in H2O
pka 4.44±0.30(Predicted)

VU0661013 price

Manufacturer Product number Product description CAS number Packaging Price Updated Buy
ApexBio Technology A8783 VU661013 2131184-57-9 5mg $866 2021-12-16 Buy
ApexBio Technology A8783 VU661013 2131184-57-9 10mg $1339 2021-12-16 Buy
ApexBio Technology A8783 VU661013 2131184-57-9 25mg $2756 2021-12-16 Buy
ApexBio Technology A8783 VU661013 2131184-57-9 50mg $4331 2021-12-16 Buy
DC Chemicals DC12064 VU0661013 >98% 2131184-57-9 1g $3600 2021-12-16 Buy
Product number Packaging Price Buy
A8783 5mg $866 Buy
A8783 10mg $1339 Buy
A8783 25mg $2756 Buy
A8783 50mg $4331 Buy
DC12064 1g $3600 Buy

VU0661013 Chemical Properties,Uses,Production

Biological Activity

vu661013 is a novel, potent, selective mcl-1 inhibitor (ki of 97 ± 30 pm).[1]mcl-1, an anti-apoptotic bcl-2 family member, is commonly upregulated in acute myeloblastic leukemia (aml) cells. targeting anti-apoptotic proteins in aml is a key therapeutic strategy, and mcl-1 is a critical anti-apoptotic oncoprotein. [1]vu661013 reduced expansion of multiple aml cell lines in vitro. venetoclax (a bcl-2 inhibitor) and vu661013 exhibited favorable synergy in several of aml cells lines, venetoclax-resistant aml cells were sensitive to vu661013. [1]vu661013 decreased tumor growth in an in vivo murine model. vu661013 (25mg/kg) and venetoclax (15mg/kg) can be synergistic in patient-derived xenograft transplantation models. [1][1]a novel mcl-1 inhibitor combined with venetoclax rescues venetoclax resistant acute myelogenous leukemia. cancer discov. 2018 sep 5. pmid: 30185627. doi: 10.1158/2159-8290.cd-18-0140

VU0661013 Preparation Products And Raw materials

Raw materials

Preparation Products

VU0661013 Suppliers

Global( 22)Suppliers
Supplier Tel Email Country ProdList Advantage
TargetMol Chemicals Inc.
+1-781-999-5354 +1-00000000000 marketing@targetmol.com United States 19892 58
InvivoChem
+1-708-310-1919 +1-13798911105 sales@invivochem.cn United States 6393 58
Nantong HI-FUTURE Biology Co., Ltd.
+undefined18051384581 sales@chemhifuture.com China 3136 58
LEAPCHEM CO., LTD.
+86-852-30606658 market18@leapchem.com China 43348 58
Aladdin Scientific
+1-833-552-7181 sales@aladdinsci.com United States 52927 58
Shanghai Lollane Biological Technology Co.,Ltd. 021-52996696,15000506266 15000506266 China 4121 55
ShangHai Biochempartner Co.,Ltd 17754423994 17754423994 2853530910@QQ.com China 8011 62
Shanghai Changyu Medical Technology Co. Ltd. +86-13301875428 sales@changyuhe.com China 289 58
Fan De(Beijing) Biotechnology Co., Ltd. 15911056312 liming@bio-fount.com China 9730 58
DC Chemicals 021-58447131 13564518121 sales@dcchemicals.com China 9414 58

VU0661013 Spectrum

VU0661013 VU661013 1H-Indole-5-carboxylic acid, 3-[(4R)-7-chloro-10-[3-(4-chloro-3,5-dimethylphenoxy)propyl]-3,4-dihydro-4-methyl-1-oxo-6-(1,3,5-trimethyl-1H-pyrazol-4-yl)pyrazino[1,2-a]indol-2(1H)-yl]-1-methyl- 2131184-57-9 C39H39Cl2N5O4